Results 191 to 200 of about 390,704 (258)

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

The Tale of the Residual Tail: Insights From Continuous Intracranial Monitoring From Post‐Hippocampectomy Dynamics

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Subtotal hippocampal resection can leave residual hippocampal tissue, yet the immediate postoperative electrophysiologic evolution of such remnants is unknown. We describe a patient with drug‐resistant temporal lobe epilepsy in whom a hippocampal remnant was continuously monitored using a responsive neurostimulator (RNS) following subtotal ...
Patrick Hartnett, Syeda Amrah Hashmi, Amaan Qureshi, Heather Spader, Shayan Moosa, Ifrah Zawar   +5 more
wiley   +1 more source

Immunogenicity of adalimumab in patients with noninfectious uveitis based on therapeutic drug monitoring. [PDF]

J Transl Med
Han JW, Zhou Y, Guo J, Chen X.
europepmc   +1 more source

Percutaneous extraction using sponge spicules for disease diagnosis and therapeutic drug monitoring. [PDF]

Sci Rep
Li S, Zhang S, Jia M, Chen S, Zhang R, Liu Y, Yan G, Chen M.   +7 more
europepmc   +1 more source

Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring

Annals of Clinical and Translational Neurology, EarlyView.
Francesco Saccà, Ryan Pelto
wiley   +1 more source

Isavuconazole: Need for therapeutic drug monitoring and CYP polymorphism testing. [PDF]

Med Mycol Case Rep
Soman R, Mayya S, Doshi R, Singh I, Ganpule S.   +4 more
europepmc   +1 more source

Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”

Annals of Clinical and Translational Neurology, EarlyView.
Lea Gerischer, Jutta Schroeder‐Braunstein, Guido Wabnitz, Andreas Meisel   +3 more
wiley   +1 more source

Saliva Based Clozapine Therapeutic Drug Monitoring: A Systematic Review. [PDF]

Pharmacol Res Perspect
Rademaker T, Chu R, Hasan S, Harris A, Alffenaar JW.   +4 more
europepmc   +1 more source